Table 4.
Sensitivity analyses results
| Analysis | Discounted quality-adjusted life expectancy, QALYs | Discounted combined costs, SEK | ICER based on combined costs, SEK per QALY gained | ||||
|---|---|---|---|---|---|---|---|
| MiniMed 780G | isCGM plus MDI or CSII | Difference | MiniMed 780G | isCGM plus MDI or CSII | Difference | ||
| Base case | 14.25 | 12.31 | + 1.95 | 3,414,589 | 2,687,181 | + 727,408 | 373,700 |
| HbA1c reduction of − 0.8% with 780G | 14.36 | 12.31 | + 2.05 | 3,369,655 | 2,687,181 | + 682,474 | 332,476 |
| HbA1c reduction of − 0.7% with 780G | 14.33 | 12.31 | + 2.02 | 3,387,534 | 2,687,181 | + 700,353 | 346,607 |
| HbA1c reduction of − 0.6% with 780G | 14.30 | 12.31 | + 1.99 | 3,399,454 | 2,687,181 | + 712,272 | 358,016 |
| HbA1c reduction of − 0.4% with 780G | 14.22 | 12.31 | + 1.92 | 3,429,771 | 2,687,181 | + 742,590 | 387,755 |
| Baseline HbA1c of 7.5% in the 780G arm | 16.24 | 12.31 | + 3.94 | 3,673,633 | 2,687,181 | + 986,452 | 250,547 |
CSII continuous subcutaneous insulin infusion, HbA1c glycated hemoglobin, ICER incremental cost-effectiveness ratio, isCGM intermittently scanned continuous glucose monitor, MDI self-injection of multiple daily insulin doses, QALY quality-adjusted life year, SEK Swedish krona